The Investor
27 Mar 2026, 20:55
AstraZeneca announced that its investigational drug Tozorakimab met primary endpoints in two Phase III trials (OBERON and TITANIA) for chronic obstructive pulmonary disease (COPD).
The studies showed that tozorakimab significantly reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo, across both former smokers and the broader patient population. The treatment was also reported to be well tolerated with a favorable safety profile.
Tozorakimab is a potential first-in-class therapy targeting interleukin-33 (IL-33), designed to reduce inflammation and address mucus dysfunction—key drivers of COPD progression.
The results mark the first successful Phase III confirmation for an IL-33–targeting biologic in COPD, a disease affecting nearly 400 million people globally. AstraZeneca plans to present detailed data at upcoming medical conferences while continuing additional late-stage trials.
The studies showed that tozorakimab significantly reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo, across both former smokers and the broader patient population. The treatment was also reported to be well tolerated with a favorable safety profile.
Tozorakimab is a potential first-in-class therapy targeting interleukin-33 (IL-33), designed to reduce inflammation and address mucus dysfunction—key drivers of COPD progression.
The results mark the first successful Phase III confirmation for an IL-33–targeting biologic in COPD, a disease affecting nearly 400 million people globally. AstraZeneca plans to present detailed data at upcoming medical conferences while continuing additional late-stage trials.